Microbes do not stop at national borders, so an infectious disease threat anywhere is a threat everywhere. Making our world safer from epidemics means strengthening the capacity of countries to prevent, detect and respond effectively to current and emerging health threats.

Strengthening global health security must start by protecting people from diseases they face today. HIV, TB and malaria are three of the world’s largest infectious disease killers, accounting for 3 million deaths in 2016 alone.

More people are on the move than ever before, with 244 million people moving across borders in 2015. Climate change is increasing the exposure of humans to vector-borne diseases. In our interconnected world of rapid global travel, every country is vulnerable to new and drug-resistant “superbugs.” While causing tragic deaths and suffering, infectious diseases can also hurt economic growth and trade, increase migration and threaten development and stability.

With a mandate to end HIV, TB and malaria as epidemics, the Global Fund partnership plays a leading role in saving lives, preventing infections and fighting drug resistance for these diseases. Through investments on surveillance and laboratory capacity, training of health-care workers, supply chains and data gathering, the Global Fund is helping countries build resilient and sustainable systems for health to respond to the next infectious disease outbreak.
Protecting People from Health Threats Today

Improved access to HIV treatment has cut the number of AIDS-related deaths in half since the peak in 2005, but under 1 million died from the disease in 2017. Tuberculosis is now the leading cause of death from infectious disease, with 1.3 million deaths per year, not including HIV co-infections. An estimated 4.1 million people with TB have been missed every year and contribute to ongoing transmission; antimicrobial resistance (AMR) is a growing threat to global health security, with TB responsible for about one-third of all AMR deaths. Global malaria death rates have dropped by 60 percent since 2000, and the number of children under the age of 5 who die from malaria has been sharply reduced. But the biological threats of drug and insecticide resistance have stalled progress against malaria. In 2016, there were 5 million more cases of malaria than 2015. The Global Fund is the world’s largest financer of the fight against these diseases, and has saved 27 million lives since its founding in 2002.

The Evolving Challenge of Global Health Security

In the last decade, the world has seen dozens of deadly infectious disease outbreaks, including new diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, or previously rare illnesses like Zika. Old diseases have mutated into newer and more dangerous forms, such as H1N1 and H7N9 influenza and drug-resistant strains of age-old killers like tuberculosis and malaria. The next outbreak is a question of “when,” not “if.”

The 2014-2015 Ebola outbreak in West Africa illustrated how weak health systems can be quickly overwhelmed by the spread of a deadly infectious disease. Robust health systems that focus on prevention, detection and treatment are not only essential for ending HIV, TB and malaria as epidemics, but are our primary line of defense against outbreaks, helping countries prepare for emerging threats to regional or global health security.

Building Resilient and Sustainable Systems for Health

Strengthening health systems is essential to end epidemics, and is a strategic pillar of the Global Fund. In the most recent funding cycle, including grants that ended in 2017, 27 percent of Global Fund investments went to health systems strengthening – from training of health personnel to improved supply chain and data quality to service delivery integration. The Global Fund supports the WHO TB Supranational Reference Laboratory Network, including funding for biosafety equipment at the newest member of the network, the National TB Reference Laboratory in Cotonou, Benin, which is working to strengthen the capacity of other laboratories in West and Central Africa.

In Sierra Leone, the Global Fund is investing US$103 million between 2016 and 2018 to support the country’s efforts to rebuild its health system following the Ebola outbreak, with a focus on training health workers, improving procurement and supply chains, strengthening diagnosis and detection techniques and implementing a more effective community approach.

In Nigeria, the Global Fund and partners are investing US$20 million to support supply chain integration to address structural problems, reduce cost and speed up response times by improving the efficiency of the health product supply chain.

A nurse calls patients waiting to receive TB medication at the Connaughty Hospital clinic in Sierra Leone’s capital Freetown. The Global Fund will invest US$1.5 million in Sierra Leone to introduce treatment for multidrug-resistant TB, and is working to increase case notification of regular TB.
Fighting Antimicrobial Resistance

Antimicrobial resistance – when organisms develop resistance to antimicrobial drugs – is one of the biggest threats to our future global health and economic security. If new treatments are not found, or if resistant infections are not diagnosed in time, untreated people will transmit the new more virulent strains to others. Mosquitos can also develop resistance to insecticides, reducing our ability to fight diseases. Increased travel, migration and trade means antimicrobial resistance is a global threat.

Drug-resistant Tuberculosis

Deaths from drug-resistant TB now account for about one-third of all antimicrobial resistance deaths worldwide. Drug-resistant TB represents a potentially catastrophic risk to global health security, including to upper-income countries. Ukraine is one of the 30 countries in the world with the highest burden of multidrug-resistant forms of TB. Fighting TB in Ukraine is essential to the health security of Europe.

The Global Fund provides 65 percent of international financing for TB and is a major source of funding for the drug-resistant TB response in low- and middle-income countries.

The Global Fund is investing US$115 million in innovative programs to find “missing” cases of TB – people who go undiagnosed, untreated and unreported. The initiative supports TB programs in 12 countries that account for 55 percent of all missed cases of TB and multidrug-resistant TB (MDR-TB) worldwide. The Global Fund is also rapidly rolling out newer and more effective short-course treatments for MDR-TB.

Artemisinin Resistance in the Mekong

The Greater Mekong is ground zero for the emergence of drug-resistant malaria, which threatens a devastating setback for the region and a major shock to health security. If the resistance seen in the Mekong were to spread to India or sub-Saharan Africa it would exact a huge toll in human lives and economic losses.

The Global Fund’s Regional Artemisinin-resistance Initiative (RAI), our largest regional grant, is a coordinated effort between funders, multilateral agencies, technical partners, scientific researchers, communities, the private sector and governments. It is working: incidence rates have fallen by more than half since 2012, and death rates have plummeted by 84 percent.

HIV Drug Resistance

HIV strains that are resistant to HIV drugs (HIVDR) are a growing threat that could undermine global progress if early and effective action is not taken. Over 10 percent of people starting antiretroviral therapy have a strain of HIV that is resistant to some of the most widely used HIV medicines. Working with WHO, the Global Fund is putting a bigger focus on HIVDR surveillance, embedding program quality and efficiency, and rapidly expanding the newest treatment regimens that are more effective, cheaper, and less prone to inciting resistance.

Quick Facts: The Economic Costs of Infectious Diseases

- The 2014-2015 Ebola outbreak in West Africa killed more than 11,000 people and resulted in US$2.8 billion in economic losses in Guinea, Liberia and Sierra Leone alone.
- Failing to tackle tuberculosis will cost the world economy US$1 trillion in the next 15 years – more than the annual GDP of the Netherlands.
- WHO estimates that US$4 trillion in economic gains would be generated by eliminating malaria by 2030.
Health Care for Refugees and Migrants

In 2016, there were 40.3 million internally displaced persons worldwide and 22.5 million refugees. For refugees forced to flee to another country because of conflict or disaster, this often means moving to temporary or crowded camps where disease can easily spread and where health care is difficult to access. Many refugees also lose access to critical medications, such as for TB; drug resistance develops when people go on and off treatment. The Global Fund supports innovative approaches to reach people with prevention and treatment services wherever they go, including refugees and migrants. In the Middle East, we are supporting a regional grant to provide TB, HIV and malaria services in Syria, Yemen, Jordan and Lebanon. In Rwanda, we are working with UNHCR to address health needs for Burundian refugees, including HIV testing, counselling and treatment, indoor residual spraying of homes and schools to ward off mosquitoes, and TB screening and treatment.

Emergency Funding

The Global Fund’s policy on challenging operating environments provides flexible financing for emergency situations to allow a quick response to outbreaks. During the peak of the Ebola crisis, the Global Fund mobilized emergency funds to support an antimalarial mass drug administration in Sierra Leone. Malaria and Ebola have many of the same symptoms, so reducing the number of people going to hospital for malaria treatment was essential to allowing health workers to focus on Ebola, and helped lower the number of people exposed to Ebola. In partnership with WHO and UNICEF, the effort reached 2.5 million people, or 95 percent of targeted households.

More people are on the move than ever before. In 2015, there were 244 million people moving across borders, up by 71 million from 2000.

About the Global Fund

The Global Fund is a 21st-century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. As a partnership between governments, civil society, the private sector and people affected by the diseases, the Global Fund mobilizes and invests nearly US$4 billion a year to support programs run by local experts in more than 100 countries. By challenging barriers and embracing innovative approaches, we are working together to better serve people affected by the diseases.